PTC Therapeutics Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
PTC Therapeutics (PTCT) Misses Q3 EPS by 30c, Revenues Miss
October 29, 2019 4:54 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.06), $0.30 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $71.42 million versus the consensus estimate of $73.02 million.
Third Quarter 2019 Financial Highlights:
Total revenues were $71.4 million for the third quarter of 2019, compared to $53.6 million for the third quarter of 2018.Translarna net product revenues were $48.3 million for the third quarter of 2019, compared to $30.4 million for the third quarter of 2018. These results reflect the expanded commercialization of Translarna.Emflaza® net product revenues were $22.9 million for the third quarter of 2019, compared to... More